Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels

Kidney International

Volumn 59, Issue 4, 2001, Pages 1529-1538

  Jones, Suzanne ^a,b,c,d   Holmes, Clifford J ^a,b,c,d   Krediet, Raymond T ^a,b,c,d   Mackenzie, Ruth ^a,b,c,d   Faict, Dirk ^a,b,c,d   Tranaeus, Anders ^a,b,c,d   Williams, John D ^a,b,c,d   Coles, Gerald A ^a,b,c,d   Topley, Nicholas ^a,b,c,d   O'donoghue D ^e   Frenken, L ^f   Brown, E ^g   Walls, J ^h   Pedersen, F B ⁱ   Freese, P ⁱ   Heimburger, Olof ^j   Gokal, R ^k   Junor, B ^l   Maiorca, R ^m   Weiss, L ⁿ   Farrington, K ^o   Kristiensen, J ^p   Ahlmen J ^q   Struijk, D ^c   Brouwer, R ^r   Ryckelynck, J P ^s   Hopwood, A M ^d   more..

^a CARDIFF UNIVERSITY   (United Kingdom)

^b BAXTER HEALTHCARE CORPORATION   (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d Baxter R and D Europe   (Belgium)

^e HOPE HOSPITAL   (United Kingdom)

^f Sittard Geleen Heerlen   (Netherlands)

^g CHARING CROSS HOSPITAL   (United Kingdom)

^h LEICESTER GENERAL HOSPITAL   (United Kingdom)

ⁱ ODENSE UNIVERSITY HOSPITAL   (Denmark)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^k MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^l WESTERN INFIRMARY   (United Kingdom)

^m Ospedale Regionale Spedali Civili   (Italy)

ⁿ Centralsjukhuset   (Sweden)

^o LISTER HOSPITAL   (United Kingdom)

^p Fredericia Sykehus   (Denmark)

^q Karnsjukhuset   (Sweden)

^r MEDISCH SPECTRUM TWENTE   (Netherlands)

^s CHU Clemenceau   (France)

more..

Author keywords

Biocompatibility; Dialysate; Effluent markers; Peritoneal membrane integrity

Indexed keywords

BICARBONATE; BUFFER; CA 125 ANTIGEN; DIANEAL; DIANEAL PD4; HYALURONIC ACID; LACTIC ACID; PERITONEAL DIALYSIS FLUID; PROCOLLAGEN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSATE; DRUG FORMULATION; FEMALE; FIBROSIS; FOLLOW UP; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MESOTHELIUM CELL; MULTICENTER STUDY; PERITONEAL DIALYSIS; PERITONEUM; PH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME; WOUND HEALING;

EID: 0035071561     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2001.0590041529.x     Document Type: Article

References (76)

1. Biocompatibility of peritoneal dialysis solutions and host defence
2. Peritoneal dialysis fluid biocompatibility: Does it really matter?
3. Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH
4. Peritoneal dialysis fluid inhibition of phagocyte function: Effects of osmolality and glucose concentration
5. Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis and bactericidal activity in vitro
6. In vivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD
7. The effect of dialysate on peritoneal phagocyte oxidative metabolism
8. Bicarbonate solutions for peritoneal dialysis: A reality
9. The untoward effects of the anions of dialysis fluids
10. A controlled trial of two bicarbonate-containing dialysis fluids for CAPD: Final report
11. A randomised controlled trial of a bicarbonate- and bicarbonate/lactate-containing dialysis solution in CAPD
12. Reduced glucose degradation products in bicarbonate/lactate-buffered peritoneal dialysis solutions produced in two-chambered bags
13. Bio-compatibility of bicarbonate-buffered peritoneal dialysis fluids: Influence on mesothelial cell and neutrophil function
14. Short term clinical study with bicarbonate-containing peritoneal dialysis solution
15. Clinical experience with a 39 mmol/L bicarbonate-buffered peritoneal dialysis solution
16. Randomized long-term evaluation of bicarbonate-buffered CAPD solution
17. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain
18. Peritoneal defence in continuous ambulatory versus continuous cyclic peritoneal dialysis
19. In vivo exposure to bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improves ex vivo peritoneal macrophage function
20. Bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNFalpha secretion
21. Intraperitoneal hyaluronan production in stable continuous ambulatory peritoneal dialysis patients
22. Growth factors VEGF and TGF-beta1 in peritoneal dialysis
23. Longitudinal follow-up of CA125 in peritoneal effluent
24. Growth factors in continuous ambulatory peritoneal dialysis effluent: Their relation with peritoneal transport of small solutes
25. Dialysate cell population and cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients: Their relationship with transport parameters
26. Type I and III procollagens in CAPD: Markers of peritoneal fibrosis
27. Cancer antigen 125: A bulk marker for mesothelial cell mass in stable peritoneal dialysis patients
28. The source and possible significance of hyaluronan in the peritoneal cavity
29. Fibrosis linked to TGF-beta in yet another disease
30. Carboxyterminal propeptide of type I procollagen in ELF: Elevation in asbestosis, but not in pleural plaque disease
31. Clinical chemical methods for assessing connective tissue metabolism
32. The carboxyterminal propeptide of procollagen type I (PICP) in serum and biological fluids
33. A long-term study of bicarbonate/lactate-based peritoneal dialysis solution-Clinical benefits. The bicarbonate/lactate study grant
34. Assay of serum hyaluronic acid in clinical application
35. Statistical analysis of repeated measures data using SAS procedures
36. Linear and non-linear models for the analysis of repeated measurements
37. What is the ideal technique for testing the biocompatibility of peritoneal dialysis solutions
38. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis
39. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultrafiltration
40. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure
41. Vascular and interstitial changes in the peritoneum of CAPD patientswith peritoneal sclerosis
42. Peritoneal morphology on maintenance dialysis
43. An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis
44. Ultrastructural morphology of the peritoneum: New findings and speculations on transfer of solutes and water during peritoneal dialysis
45. The morphology of the human peritoneum in CAPD patients
46. Morphology of the peritoneal membrane during continuous ambulatory peritoneal dialysis
47. Ultrastructural studies on the peritoneum with special reference to chronic ambulatory peritoneal dialysis
48. Membrane longevity in peritoneal dialysis: Impact of infection and bio-incompatible solutions
49. Biocompatibility of a peritoneal dialysis solution with amino acids: Histological evaluation in the rabbit
50. Population analysis of mesothelium in situ and in vivo exposed to bicarbonate-buffered peritoneal dialysis fluid
51. Acute and long-term changes observed in imprints of mouse mesothelium exposed to glucose-enriched, lactated, buffered dialysis solutions
52. Biocompatibility of dialysis solutions evaluated by histochemical techniques applied to mesothelial cell imprints
53. Biocompatibility of a glucose polymer-containing peritoneal dialysis fluid
54. In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial cell and neutrophil function
55. In vitro biocompatibility of alternative CAPD fluids: Comparison of bicarbonate buffered and glucose polymer based solutions
56. Effect of euhydric peritoneal dialysis solutions containing a mixture of bicarbonate and lactate or lactate alone on neutrophilic superoxide production
57. Bicarbonate- versus lactate-based CAPD fluids: A biocompatibility study in rabbits
58. Inflammatory changes in vivo during CAPD: What can the effluent tell us?
59. Markers of peritoneal membrane status
60. CA 125 secretion by peritoneal mesothelial cells
61. Modulation of CA-125 release by inflammatory cytokines in human peritoneal mesothelial and ovarian cancer cells
62. The role of the peritoneal membrane in the control of inflammation in the peritoneal cavity
63. Activation of inflammation and leukocyte recruitment into the peritoneal cavity
64. Peritoneal dialysis induces a local sterile inflammatory state and the mesothelial cells in the effluent are related to the bacterial peritonitis incidence
65. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: A report on the Japanese sclerosing encapsulating peritonitis study group
66. Low concentrations of glucose degradation products in peritoneal dialysis fluids and their impact on biocompatibility parameters: Prospective cross-over study with a three-compartment bag
67. Clinical and physiological effects of a new, less toxic and less acidic fluid for peritoneal dialysis
68. Cytotoxicity of peritoneal dialysis fluid-Is it related to glucose breakdown products
69. Effect of glucose degradation products on human peritoneal mesothelial cell function
70. Expression of human hyaluronan synthases in response to external stimuli
71. Hyaluronan synthases
72. IL-1β, a major stimulator of hyaluronan synthesis in vitro of human peritoneal mesothelial cells: Relevance to peritonitis in CAPD
73. Increased production of hyaluronan by peritoneal cells and its significance in patients on CAPD
74. What really happens to people on long-term peritoneal dialysis?
75. Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis